Drug Trial Radar · NCT06487845
A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants
Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jul 4, 2024
Primary completion
Sep 19, 2024
Study completion Sep 19, 2024
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jul 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD) or non-proliferative diabetes retinopathy (NPDR). CKD is a long-term condition in which the ability of the kidneys to work decreases over time. It is often caused by high blood glucose levels. NPDR is another condition in which high blood glucose levels cause damage to the blood vessels of the retina, which is a tissue at the back of the eyes. The study drug BAY3283142 works by activating a protein called soluble guanylate cyclase, which helps widen the blood vessels and regulate blood flow inside the body. This may help increase the blood flow in the kidneys and improve their function. It could also help to restore blood flow to the retina. This study will include healthy participants who will not benefit from taking BAY3283142. However, the study will provide information on how to test BAY3283142 in future studies in participants with CKD or NPDR. The main purpose of this study is to check how safe single and multiple doses of BAY3283142 are in healthy Chinese participants. For this, researchers will collect the number and percentage of participants who have medical problems, which are also known as 'adverse events', after taking BAY3283142 or a placebo. A placebo looks like the study treatment but does not have any medicine in it. The study doctor will keep track of all adverse events that happen in the study, even if they are not related to the study treatments. The participants will be randomly divided into 2 treatment groups. They will take either BAY3283142 as an immediate-release tablet, or a placebo tablet, once, by mouth, based on the group assigned to them. An immediate-release tablet quickly dissolves and releases the drug inside the body. Participants will have a one-day break after taking the single dose and then continue taking their assigned treatment once daily for a week. Researchers will check two different dose strengths of BAY3283142 in this study, starting with a low dose first. Each participant will be in the study for around 7 weeks, which includes: A visit within 21 days before the first dose to confirm if the participant can take part in the study A hospital stay of 15 days during which the participant will take the assigned study treatment and the study doctor will monitor the participant's health A visit after 7 to 10 days of taking the last dose during which the study doctor will perform a health check-up of the participant During the study, the study doctor and his/her team will: Test participants' blood and urine samples and check their overall health Monitor participants' heart health by electrocardiogram (ECG) and measure their blood pressure and heart rate As this study is conducted in healthy participants who will not gain any benefit from the treatment, access to the treatment after the study is not planned.
Conditions
- Chronic Kidney Disease
- Non-proliferative Diabetic Retinopathy
- Healthy Volunteers
Interventions
BAY3283142Drug
IR tablets, oral
PlaceboDrug
Placebo matched to BAY3283142
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment emergent adverse event (TEAEs)Time frame: From first study intervention administration until [including] 7 days after end of treatment with study intervention (approximately 25 days)
- Percentage of participants with treatment emergent adverse event (TEAEs)Time frame: From first study intervention administration until [including] 7 days after end of treatment with study intervention (approximately 25 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangzhou University of TCM
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.